AtaiBeckley (ATAI) Equity Income (2020 - 2024)
AtaiBeckley's (ATAI) quarterly Equity Income came in at -$26000.0 in Q3 2024, up 89.08% year-on-year from -$13751.1 in Q4 2023, and up 90.48% quarter-over-quarter from -$273000.0 in Q2 2024.
AtaiBeckley (ATAI) Equity Income (2020 - 2024) Analysis & Trends
AtaiBeckley has disclosed Equity Income across 5 years of filings, most recently posting -$26000.0 for Q3 2024.
- Equity Income for Q3 2024 came in at -$26000.0, up 89.08% year-over-year; the trailing twelve-month figure through Jun 2025 was -$26000.0 (up 99.0% YoY), and the FY2024 annual result was -$2.0 million, up 44.34% from the prior year.
- Equity Income came in at -$26000.0 for Q3 2024 at AtaiBeckley, up from -$273000.0 in the prior quarter.
- In the past five years, Equity Income ranged from a high of -$26000.0 in Q3 2024 to a low of -$61.9 million in Q3 2020.
- The 5-year median for Equity Income is -$2.2 million (2022), against an average of -$8.6 million.
- Across the five-year window, Equity Income slumped 1645.38% in 2021 and soared 97.3% in 2022, its largest moves.
- AtaiBeckley's Equity Income stood at -$2.8 million in 2020, then plunged by 1645.38% to -$49.1 million in 2021, then jumped by 97.3% to -$1.3 million in 2022, then surged by 70.29% to -$394000.0 in 2023, then surged by 93.4% to -$26000.0 in 2024.
- The last three Equity Income figures came in at -$26000.0 (Q3 2024), -$273000.0 (Q2 2024), and -$1.7 million (Q1 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 235,807.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | AtaiBeckley | 1.45 Bn | 1.45 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | -26,000.00 |
| Jun 30, 2024 | -273,000.00 |
| Mar 31, 2024 | -1.70 Mn |
| Dec 31, 2023 | -394,000.00 |
| Sep 30, 2023 | -238,000.00 |
| Jun 30, 2023 | -1.93 Mn |
| Mar 31, 2023 | -1.03 Mn |
| Dec 31, 2022 | -1.33 Mn |
| Sep 30, 2022 | -2.43 Mn |
| Jun 30, 2022 | -6.65 Mn |
| Mar 31, 2022 | -5.60 Mn |
| Dec 31, 2021 | -49.12 Mn |
| Sep 30, 2021 | -4.80 Mn |
| Jun 30, 2021 | -2.94 Mn |
| Mar 31, 2021 | -1.70 Mn |
| Dec 31, 2020 | -2.81 Mn |
| Sep 30, 2020 | -61.86 Mn |
| Jun 30, 2020 | -9.81 Mn |